Media Contacts
photo:Caitlin Pearson
Caitlin Pearson
Corporate Communications
Share this release
Share on: Twitter
Share on: Facebook
Share on: LinkedIn
Latest news
11
February
2016
|
16:56
Europe/Amsterdam

Appointment of Vice President of Tissue Regenix Orthopaedic, Inc. North America

York, 11 February 2016 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix") or ("The Group") the regenerative medical devices company, is pleased to announce the appointment of Drew Distin as Vice President ("VP") of the Group's recently established subsidiary, Tissue Regenix Orthopaedic, Inc. North America. Drew will commence the role as of March 1st 2016.

Drew is well respected within the Orthopaedic sector in the United States having held a number of senior sales and business development roles at Parkus Medical, LLC. Osiris Therapeutics, Inc. Nuortho Surgical, Inc. RTI Biologics, Inc. and CryoLife, Inc.

With specialist knowledge in maximising sales through targeted marketing, he joins Tissue Regenix as it embarks on the next stage of commercialisation with its dCELL® Orthopaedic applications. His focus will be to drive their entry into the US marketplace in the coming years, with the first step expected to begin in 2017.

Currently, the Group have ongoing clinical trials for the OrthoPure XM (Porcine meniscus) and OrthoPure XT (Porcine tendon) products within the EU and aim to achieve CE mark submission by the end of the year for XM.

In the US, it is expected that the market entry strategy will focus on human tissue applications, initially starting with the human tendon (OrthoPure HT). Tissue Regenix is currently in partnership with tissue bank Community Tissue Services (CTS) for the manufacturing of its wound care product DermaPure®, and this licencing model is one which the Group expects to replicate with relevant Orthopaedic partners.

Peter Hamer, Commercial Director, Tissue Regenix Orthopaedic Ltd, said:

"We are delighted to welcome Drew to the Orthopaedic team. He brings with him a wealth of experience that will be advantageous throughout the next stages of our commercialisation and the expansion of our Orthopaedic portfolio. This is a very exciting time for Orthopaedics at Tissue Regenix as we continue enrolment of our OrthoPure XT clinical trial and await submission for the CE mark with OrthoPure XM. We are on course to complete these tasks within the timeline predicted and look forward to further expansion into the US with Drew on board."